advertisement
Abstract #10923 Published in IGR 6-2
Are there any benefits of Betoptic® S (betaxolol HCl ophthalmic suspension) over other β-blockers in the treatment of glaucoma?
Yarangumeli A; Kural GExpert Opinion in Pharmacotherapy 2004; 5: 1071-1081
The cardioselective β-blocker, betaxolol, is an effective ocular antihypertensive agent. Its mode of action in lowering intraocular pressure is similar to that of the nonselective blockers, by suppressing the flow of aqueous humor. The most frequent adverse reaction to betaxolol is stinging upon administration, which is minimised by an ocular suspension with a similarly effective twofold reduced concentration (BetopticR S, 0.25%). The extent of β1-adrenoceptor occupancy of topically applied betaxolol in the systemic circulation is less than that of the nonselective blockers and β2-receptor occupancy is negligible, providing a better safety profile in patients with cardiopulmonary disease. Experimental studies have revealed that the drug reaches the retina after topical administration and displays a voltage-dependent L-type calcium channel blocking activity, which probably allows betaxolol to improve retinal perfusion and to serve as a neuroprotective agent recommendable in various forms of glaucoma.
Dr. A. Yarangumeli, Guvenlik Cad 22/15, A.Ayranci 06540 Ankara
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)